cellvie

We beat the odds - Under the highly competitive Swiss Innovation Project (SIP) scheme, Innosuisse will support cellvie's CHF 2.1 Million project to further establish #mitochondria-enabled #genetherapy. The grant is a testament to the innovativeness as well as the potential of leveraging mitochondria to carry oligonucleotides to places where no therapeutic RNA has gone before. This achievement would not have been possible without the relentless work of the team at cellvie. Thank you Dedy Septiadi, PhD, Gabriele Alessandro Fontana, Laura Sbaragli, Julia Wawrzyniak, This Egloff, Federica Z., Stephen Helliwell, and Martijn Brugman for your great work, which is clearly bearing fruits! We strongly believe that mitochondria hold three distinct advantages over LNPs or viral vectors: 1) Tissue specificity - preliminary studies have shown that mitochondria can be used to minimally invasively deliver oligonucleotides to solid organs outside of the liver. 2) Improved safety - without any meaningful immune response even at high doses, and their degradation within days to weeks, mitochondria can be relied on for high and repeated dosing 3) Payload capacity - as a considerably larger carrier when compared to viral vectors and LNPs, mitochondria can carry more molecules per particle, very large oligonucleotides, and different oligonucleotides at the same time. The mitochondria are taken up through endocytosis and are capable of releasing their payload into the cytoplasm.

We are growing our team to accelerate the development of our #mitochondria platform. If you have hands on research experience with mitochondria, are eager to join an entrepreneurial journey and become part of a caring team, reach out!

Our #CSO, Stephen Helliwell will be speaking at the #TargetingMitochondria2024 conference, sharing the latest data in progressing our allogeneic off-the-shelf #mitochondria towards clinical translation!

cellvie and our work on #mitochondriatransplantation was featured in one of Germany's most prolific newspapers, the Frankfurter Allgemeine Zeitung in their special feature on #longevity. A worthwhile read by Vanessa Trzewik and Roland Lindner! Thank you for including us alongside other pioneers in longevity like Michael Greve and Bryan Johnson!

cellvie's co-founder and CEO, Dr. Alexander Schueller spoke at Kizoo Ventures's Rejuvenation Startup Summit in Berlin, highlighting the potential that #mitochondria hold as a therapeutic modality and sharing the progress we made on product development and understanding of the mechanism of mitochondria transplantation along with the results of cellvie's recent studies in #kidney ischemia-reperfusion injury.

It's been a while since this video was shot by Dr. Alexander Schueller as part of the MedTech Innovator accelerator, when we were pursuing mitochondria transplantation as a device-enabled therapy. We have come a long way, now developing an allogeneic off-the-shelf product. But the key messages still apply: we are seeking to give a fighting chance to patients who suffered from #ischemia #reperfusion injury. https://lnkd.in/dRBMUsDp

Leveraging the therapeutic potential of mitochondria   cellvie secures Innosuisse grant with CSEM to advance their mitochondria-based therapy platform.     The funded project focuses on advancing cellvie’s mitochondria isolation process to enable the scalable, safe, and cost-effective manufacturing of its therapy. Read more here: https://rb.gy/g2syu5   Dr. Alexander Schueller Stephen Helliwell Martijn Brugman Charlotte Fonta Diane Ledroit-Paic Vincent Revol Gilles Weder Elise Aeby